Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 16/20 | 0.49 |
| ▸ | LOX | P28300 | 5/20 | 0.49 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL568429 | 0.98 | LOXL2 (0.47) | LOXL2LOXLOXL3ROCK1PSIP1 | |
| Trifluoroacetic Acid SCHEMBL1873566 | 0.87 | LOXL2 (0.45) | LOXL2LOXLOXL3CCR1KCNH2 | |
| Hydrochloric Acid SCHEMBL2170122 | 0.84 | LOXL2 (0.41) | LOXL2LOX | |
| SCHEMBL2643052 | 0.84 | LOXL2 (0.47) | LOXL2LOXLOXL3ROCK1PSIP1 | |
| SCHEMBL13180198 | 0.83 | NOS3 (0.50) | NOS3NOS1NOS2CCR1KCNH2 | |
| SCHEMBL3126699 | 0.83 | LOXL2 (0.50) | LOXL2LOXLOXL3ROCK1 | |
| SCHEMBL2644511 | 0.83 | CCR1 (0.36) | LOXL2LOXNOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL2170595 | 0.82 | HRH1 (0.39) | LOXL2LOXCCR1KCNH2 | |
| SCHEMBL15550019 | 0.82 | HRH3 (0.44) | LOXL2LOXROCK1PSIP1NOS3 | |
| SCHEMBL17266362 | 0.81 | CCR1 (0.38) | LOXL2LOXNOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023076567-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | ANOVIA BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8927550-B2 | Heterocyclic compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8927550-B2 | Heterocyclic compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8927550-B2 | Heterocyclic compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| EP-2493875-B1 | HETEROCYCLIC COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-06 | — | — | EP | disclosed |
| EP-2493875-B1 | HETEROCYCLIC COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-8765789-B2 | 2-pyridinecarboxamide derivatives | MSD K.K. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20130085156-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-7879873-B2 | Azaindazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-7879873-B2 | Azaindazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010036632-A1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036632-A1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-7629362-B2 | 2-pyridine carboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | LOXL2 3029/4885LOX 3862/4885LOXL3 2957/4885 |
| US-20130085156-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | LOXL2 2232/4885LOX 1831/4885LOXL3 2283/4885 |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | GCKR, GCK, HK2 | LOXL2 2252/4885LOX 1812/4885LOXL3 2209/4885 |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | LOXL2 2232/4885LOX 1831/4885LOXL3 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.